Cargando…
A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer
BACKGROUND: Persistent opioid use frequently leads to substantial negative impacts on quality of life, and as the outlook for numerous cancer types continues to improve, these complications become increasingly crucial. It is essential to acknowledge that extended or excessive opioid use may result i...
Autores principales: | Horinouchi, Ai, Enokida, Tomohiro, Suzuki, Shinya, Kamata, Hayato, Kaneko, Asumi, Matsuyama, Chihiro, Fujisawa, Takao, Ueda, Yuri, Ito, Kazue, Okano, Susumu, Kawasaki, Toshikatsu, Tahara, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541207/ https://www.ncbi.nlm.nih.gov/pubmed/37781181 http://dx.doi.org/10.3389/fonc.2023.1145323 |
Ejemplares similares
-
Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib
por: Suzuki, Shinya, et al.
Publicado: (2020) -
Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023) -
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018) -
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018) -
Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)